Alaina Van Dyke
Research Subjects
Alaina Van Dyke has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Carly Lacey
Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center
1 shared publication - Carroll
DCH Regional Medical Center
1 shared publication - Christina Louise Mnatzaganian
University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, and University of California San Diego Health , La Jolla, CA
1 shared publication - Kristine M. Cline
The Ohio State University College of Pharmacy, Columbus, OH, 500 W. 12th Avenue, Columbus, OH 43210
1 shared publication - Maria Miller Thurston
Mercer University, College of Pharmacy, Atlanta, Georgia
1 shared publication - Rachel Basinger
Texas Tech University Health Sciences Center
1 shared publication
Latest Publications
- 28 June 2025
- Published by Springer Nature
- p. 265-276
Non-pharmacologic Interventions for Overweight and Obesity
- 28 June 2025
- Published by Springer Nature
- p. 265-276
Non-pharmacologic Interventions for Overweight and Obesity
- 28 June 2025
- Published by Springer Nature
- p. 41-68
Non-pharmacologic Interventions for Type 2 Diabetes
- 7 September 2024
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 88 (11) , 101286
Prioritizing Faculty Well-Being: Why it Matters, What Schools Can Do, and a Call for Action
- 7 September 2024
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 88 (11) , 101286
Prioritizing Faculty Well-Being: Why it Matters, What Schools Can Do, and a Call for Action
- Open Access
- 2 April 2022
- Published by University of Minnesota in INNOVATIONS in pharmacy
- Vol. 13 (1) , 7
Assessment of Direct Oral Anticoagulant Use at a Community Teaching Hospital
Direct oral anticoagulants (DOACs) have become popular choices for both the treatment and prevention of thromboembolic events. However, these agents pose additional risks to patients due to complex dosing, insufficient monitoring, and inconsistent patient compliance. This study evaluates the appropriateness of DOAC prescribing for patients who received an order for apixaban or rivaroxaban over a 6-month period. The primary outcome is percentage of inappropriately prescribed DOAC regimens. Secondary outcomes include an effectiveness endpoint of stroke or embolism and a safety endpoint of major bleeding documented during or within 60 days of the initial visit as well as number of pharmacist clinical interventions. DOAC orders were appropriate 73% of the time. Of the 27% of inappropriate orders, approximately half were apixaban and half were rivaroxaban. The most common reason for an inappropriate order for apixaban was due to atrial fibrillation dosing, and the most common reason for an inappropriate rivaroxaban order was due to dose-indication mismatch. There were 30 pharmacist clinical interventions on DOAC orders that were documented during the 6-month period, and the most common reason for a pharmacist intervention was duplication with another anticoagulant.
- 2 April 2022
- Published by University of Minnesota in INNOVATIONS in pharmacy
- Vol. 13 (1) , 7
Open AccessAssessment of Direct Oral Anticoagulant Use at a Community Teaching Hospital
Direct oral anticoagulants (DOACs) have become popular choices for both the treatment and prevention of thromboembolic events. However, these agents pose additional risks to patients due to complex dosing, insufficient monitoring, and inconsistent patient compliance. This study evaluates the appropriateness of DOAC prescribing for patients who received an order for apixaban or rivaroxaban over a 6-month period. The primary outcome is percentage of inappropriately prescribed DOAC regimens. Secondary outcomes include an effectiveness endpoint of stroke or embolism and a safety endpoint of major bleeding documented during or within 60 days of the initial visit as well as number of pharmacist clinical interventions. DOAC orders were appropriate 73% of the time. Of the 27% of inappropriate orders, approximately half were apixaban and half were rivaroxaban. The most common reason for an inappropriate order for apixaban was due to atrial fibrillation dosing, and the most common reason for an inappropriate rivaroxaban order was due to dose-indication mismatch. There were 30 pharmacist clinical interventions on DOAC orders that were documented during the 6-month period, and the most common reason for a pharmacist intervention was duplication with another anticoagulant.